Compare Amgen, Inc. (AMGN) vs AXT Inc (AXTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs AXT Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while AXT Inc trades at $55.54 (market cap $3.74B). The key difference: Amgen, Inc. is far larger — about 52.4× AXT Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while AXT Inc pays none. Which is the better fit depends on your goals.
| AMGN | AXTI | |
|---|---|---|
Market Cap | $196.12B | $3.74B |
Sector | Health | Technology |
52-Week High | $388.16 | $140.83 |
52-Week Low | $271.18 | $1.92 |
Enterprise Value | $241.41B | $3.71B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
AXTI trades at $57.21, down 8.54% today amid bearish technical signals. The company shows negative profitability with a -14.68% net margin but has beaten EPS estimates in two of the last three quarters. Analyst consensus is bullish with 64% buy ratings, supported by a $100M backlog and AI-driven indium phosphide demand growth. Cash flow remains positive primarily from financing activities.
Near-term outlook hinges on Q2 2026 earnings due July 30, where analysts expect EPS of $0.07. Key opportunities include AI infrastructure expansion and capacity growth, while risks involve geopolitical tensions affecting Chinese exports and ongoing negative cash flow from operations. The stock faces resistance near $66 with support at $55.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →
